One Hundred Courses of Cluster Maintenance Transcranial Magnetic Stimulation (CM TMS)-A Clinical Audit Study

Affiliations

27 October 2022


Abstract

Objective: Major depressive disorder (MDD) which comes to transcranial magnetic stimulation (TMS) is prone to relapse. Cluster maintenance (CM) TMS is courses of 5 treatments delivered over 2.5-5 days, separated by monthly or greater non-treatment periods. Our aim was to characterize the outcomes of 100 courses of CM TMS.

Method: This was a Quality Assurance/Clinical Audit study. We studied consecutive CM TMS courses provided to private hospital inpatients. Mood was rated (on admission and discharge) using the six-item Hamilton depression rating (HAMD6) and the Clinical Global Impression - Severity (CGI-S) scales. We also applied recent STAR*D criteria which are designed to measure the 'clinical change' expected to impact patient function [16].

Results: For the total sample, using the HAMD6, 83% of courses featured relapse or partial relapse on admission, and 81% featured remission on discharge. Of 46 courses featuring HAMD6 relapse on admission, 74% featured remission on discharge. For the 100 courses the HAMD6 discharge scores were significantly lower than the admission scores (p = 2.0 × 10-24), as were the CGI-S scores (p = 1.8 × 10-25). Using STAR*D criteria for people in relapse or partial relapse on admission, CM TMS provided least a 'clinically meaningful' outcome in 82% of the cases.

Conclusion: For courses featuring relapse or partial relapse on admission, CM TMS converted greater than 70% to remission at discharge. It produced statistically significant reductions in HAMD6 and CGI-S scores, and using STAR*D criteria, at least 'clinically meaningful' change was extensively demonstrated. This evidence indicates CM TMS should be readily available to people living with relapsing MDD.

Keywords: maintenance treatment; major depressive disorder; relapse; remission; transcranial magnetic stimulation.


Similar articles

The impact of transcranial magnetic stimulation (TMS) on irritability occurring with acute major depressive disorder (MDD).

Pridmore S, Rybak M, Morey R, May T.Australas Psychiatry. 2021 Apr;29(2):218-221. doi: 10.1177/1039856220946606. Epub 2020 Aug 10.PMID: 32772718

Early relapse (ER) transcranial magnetic stimulation (TMS) in treatment resistant major depression.

Pridmore S, Erger S, Rybak M, Kelly E, May T.Brain Stimul. 2018 Sep-Oct;11(5):1098-1102. doi: 10.1016/j.brs.2018.05.013. Epub 2018 May 22.PMID: 29805096

Second Courses of Transcranial Magnetic Stimulation (TMS) in Major Depressive Episodes for Initial Responders and Non-Responders.

Pridmore S, Erger S, May T.Malays J Med Sci. 2019 May;26(3):102-109. doi: 10.21315/mjms2019.26.3.8. Epub 2019 Jun 28.PMID: 31303854 Free PMC article.

Maintenance treatment of transcranial magnetic stimulation (TMS) for treatment-resistant depression patients responding to acute TMS treatment.

Chang J, Chu Y, Ren Y, Li C, Wang Y, Chu XP.Int J Physiol Pathophysiol Pharmacol. 2020 Oct 15;12(5):128-133. eCollection 2020.PMID: 33224435 Free PMC article. Review.

Novel Augmentation Strategies in Major Depression.

Martiny K.Dan Med J. 2017 Apr;64(4):B5338.PMID: 28385173 Review.


KMEL References